Cytokine therapy of mycobacterial infections

Advances in Internal Medicine

Volumn 45, Issue , 2000, Pages 431-452

  Holland, Steven M ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 12; INTERLEUKIN 2; THALIDOMIDE;

ANTIBIOTIC RESISTANCE; DRUG COMBINATION; HUMAN; IMMUNE DEFICIENCY; IMMUNOTHERAPY; MYCOBACTERIOSIS; REVIEW; TUBERCULOSIS;

ADJUVANTS, IMMUNOLOGIC; ANTI-INFECTIVE AGENTS; CYTOKINES; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-2; MYCOBACTERIUM INFECTIONS; THALIDOMIDE; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 0033630312     PISSN: 00652822     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (96)

1. Castro KG: Global tuberculosis challenges. Emerg Infect Dis 4:408-409, 1998.
2. Horsburgh CR Jr, Mason UG, Farhi DC, et al: Disseminated infection with Mycobacterium avium-intracellulare: A report of 13 cases and a review of the literature. Medicine (Baltimore) 64:36-48, 1985.
3. Altare F, Jouanguy E, Lamhamedi S, et al: Mendelian susceptibility to mycobacterial infection in man. Curr Opin Immunol 10:413-417, 1998.
4. Dorman SE, Uzel G, Billman G, et al: Severe viral infections in interferon gamma receptor deficiency. J Pediatr, in press.
5. Koch R: Forsetzung der mittheilung uber ein heilmittel gegen tuberkulose. Dtsch Med Wochenschr 17:101, 1891.
6. Trudeau EL: Tuberculin immunization in the treatment of pulmonary tuberculosis. Am J Med Sci 133:813-829, 1907.
7. Rich AR: The Pathogenesis of Tuberculosis. Springfield, Ill, Charles Thomas, 1951, pp 555-569.
8. Engbaek HC: Three cases in the same family of fatal infection with M. avium. Acta Tubercle Scand 45:105-117, 1964.
9. Fischer A, Virelizier JL, Griscelli C, et al: Defective monocyte functions in a child with fatal disseminated BCG infection. Clin Immunol Immunopathol 17:296-306, 1980.
10. Uchiyama N, Greene GR, Warren BJ, et al: Possible monocyte killing defect in familial atypical mycobacteriosis. J Pediatr 98:785-788, 1981.
11. Holland SM, Eisenstein EM, Kuhns DB, et al: Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma: A preliminary report. N Engl J Med 330:1348-1355, 1994.
12. Frucht DM, Holland SM: Defective monocyte costimulation for IFN-gamma production in familial disseminated Mycobacterium avium complex infection: Abnormal IL-12 regulation. J Immunol 157:411-416, 1996.
13. Frucht DM, Sandberg DI, Brown MR, et al: IL-12-independent co-stimulation pathways for interferon-gamma production in familial disseminated Mycobacterium avium complex infection. Clin Immunol 91:234-241, 1999.
14. Levin M, Newport MJ, D'Souza S, et al: Familial disseminated atypical mycobacterial infection in childhood: A human mycobacterial susceptibility gene? Lancet 345:79-83, 1995.
15. Newport MJ, Huxley CM, Huston S, et al: A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N Engl J Med 335:1941-1949, 1996.
16. Jouanguy E, Altare F, Lamhamedi S, et al: Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection. N Engl J Med 335:1956-1961, 1996.
17. Jouanguy E, Lamhamedi-Cherradi S, Altare F, et al: Partial interferon-gamma receptor 1 deficiency in a child with tuberculoid bacillus Calmette-Guerin infection and a sibling with clinical tuberculosis. J Clin Invest 100:2658-2664, 1997.
18. Holland SM, Dorman SE, Kwon A, et al: Abnormal regulation of interferon-gamma, interleukin-12, and tumor necrosis factor-alpha in human interferon-gamma receptor 1 deficiency. J Infect Dis 178:1095-1104, 1998.
19. Dorman SE, Holland SM: Mutation in the signal-transducing chain of the interferon-gamma receptor and susceptibility to mycobacterial infection. J Clin Invest 101:2364-2369, 1998.
20. Altare F, Durandy A, Lammas D, et al: Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 280:1432-1435, 1998.
21. de Jong R, Altare F, Haagen IA, et al: Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science 280:1435-1438, 1998.
22. Altare F, Lammas D, Revy P, et al: Inherited interleukin 12 deficiency in a child with bacille Calmette-Guerin and Salmonella enteritidis disseminated infection. J Clin Invest 102:2035-2040, 1998.
23. Jouanguy E, Lamhamedi-Cherradi S, Lammas D, et al: A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection. Nat Genet 21:370-378, 1999.
24. Murray HW: Current and future clinical applications of interferon-gamma in host antimicrobial defense. Intensive Care Med 22:456S-461S, 1996.
25. Boehm U, Klamp T, Groot M, et al: Cellular responses to interferon-γ. Annu Rev Immunol 15:749-795, 1997.
26. Darnell JE Jr: Studies of IFN-induced transcriptional activation uncover the Jak-Stat pathway. J Interferon Cytokine Res 18:549-554, 1998.
27. Appelberg R, Orme IM: Effector mechanisms involved in cytokine-mediated bacteriostasis of Mycobacterium avium infections in murine macrophages. Immunology 80:352-359, 1993.
28. Flesch IE, Kaufmann SH: Attempts to characterize the mechanisms involved in mycobacterial growth inhibition by gamma-interferon-activated bone marrow macrophages. Infect Immun 56:1464-1469, 1988.
29. Adams LB, Dinauer MC, Morgenstern DE, et al: Comparison of the roles of reactive oxygen and nitrogen intermediates in the host response to Mycobacterium tuberculosis using transgenic mice. Tuber Lung Dis 78:237-246, 1997.
30. Bermudez LE, Young LS: Oxidative and non-oxidative intracellular killing of Mycobacterium avium complex. Microb Pathog 7:289-298, 1989.
31. Denis M, Gregg EO, Ghandirian E: Cytokine modulation of Mycobacterium tuberculosis growth in human macrophages. Int J Immunopharmacol 12:721-727, 1990.
32. Douvas GS, Looker DL, Vatter AE, et al: Gamma interferon activates human macrophages to become tumoricidal and leishmanicidal but enhances replication of macrophage-associated mycobacteria. Infect Immun 50:1-8, 1985.
33. Flynn JL, Chan J, Triebold KJ, et al: An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 178:2249-2254, 1993.
34. Cooper AM, Dalton DK, Stewart TA, et al: Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 178:2243-2247, 1993.
35. Kamijo R, Le J, Shapiro D, et al: Mice that lack the interferon-gamma receptor have profoundly altered responses to infection with bacillus Calmette-Guerin and subsequent challenge with lipopolysaccharide. J Exp Med 178:1435-1440, 1993.
36. Kamijo R, Harada H, Matsuyama T, et al: Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. Science 263:1612-1615, 1994.
37. Doherty TM, Sher A: Defects in cell-mediated immunity affect chronic, but not innate, resistance of mice to Mycobacterium avium infection. J Immunol 158:4822-4831, 1997.
38. Edwards CK, Hedegaard HB, Zlotnik A, et al: Chronic infection due to Mycobacterium intracellulare in mice: Association with macrophage release of prostaglandin E2 and reversal by injection of indomethacin, muramyl dipeptide, or interferon-gamma. J Immunol 136:1820-1827, 1986.
39. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease: The International Chronic Granulomatous Disease Cooperative Study Group. N Engl J Med 324:509-516, 1991.
40. Bemiller LS, Roberts DH, Starko KM, et al: Safety and effectiveness of long-term interferon gamma therapy in patients with chronic granulomatous disease. Blood Cells Mol Dis 21:239-247, 1995.
41. Gallin JI, Farber JM, Holland SM, et al: Interferon-gamma in the management of infectious diseases. Ann Intern Med 123:216-224, 1995.
42. Nathan CF, Kaplan G, Levis WR, et al: Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy. N Engl J Med 315:6-15, 1986.
43. Sampaio EP, Moreira AL, Sarno EN, et al: Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients. J Exp Med 175:1729-1737, 1992.
44. Sampaio EP, Kaplan G, Miranda A, et al: The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 168:408-414, 1993.
45. Sampaio EP, Malta AM, Sarno EN, et al: Effect of rhuIFN-gamma treatment in multibacillary leprosy patients. Int J Lepr Other Mycobact Dis 64:268-273, 1996.
46. Squires KE, Murphy WF, Madoff LC, et al: Interferon-gamma and Mycobacterium avium-intracellulare infection. J Infect Dis 159:599-600, 1989.
47. Squires KE, Brown ST, Armstrong D, et al: Interferon-gamma treatment for Mycobacterium avium-intracellulare complex bacillemia in patients with AIDS (letter). J Infect Dis 166:686-687, 1992.
48. Pierre-Audigier C, Jouanguy E, Lamhamedi S, et al: Fatal disseminated Mycobacterium smegmatis infection in a child with inherited interferon gamma receptor deficiency. Clin Infect Dis 24:982-984, 1997.
49. Altare F, Jouanguy E, Lamhamedi-Cherradi S, et al: A causative relationship between mutant IFNgR1 alleles and impaired cellular response to IFNgamma in a compound heterozygous child (letter). Am J Hum Genet 62:723-726, 1998.
50. Vesterhus P, Holland SM, Abrahamsen TG, et al: Familial disseminated infection due to atypical mycobacteria with childhood onset. Clin Infect Dis 27:822-825, 1998.
51. Olivier KN: Nontuberculous mycobacterial pulmonary disease. Curr Opin Palm Med 4:148-153, 1998.
52. Prince DS, Peterson DD, Steiner RM, et al: Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med 321:863-868, 1989.
53. Iseman MD, Buschman DL, Ackerson LM: Pectus excavatum and scoliosis: Thoracic anomalies associated with pulmonary disease caused by Mycobacterium avium complex. Am Rev Respir Dis 144:914-916, 1991.
54. Reich JM, Johnson RE: Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern: The Lady Windermere syndrome. Chest 101:1605-1609, 1992.
55. Griffith DE, Wallace RJ Jr: New developments in the treatment of non-tuberculous mycobacterial (NTM) disease. Semin Respir Infect 11:301-310, 1996.
56. Wallace RJ Jr, Zhang Y, Brown BA, et al: Polyclonal Mycobacterium avium complex infections in patients with nodular bronchiectasis. Am J Respir Crit Care Med 158:1235-1244, 1998.
57. Jaffee HA, Buhl R, Mastrangeli A, et al: Organ specific cytokine therapy: Local activation of mononuclear phagocytes by delivery of an aerosol of recombinant interferon gamma to the human lung. J Clin Invest 88:297-302, 1991.
58. Chatte G, Panteix G, Perrin-Fayolle M, et al: Aerosolized interferon gamma for Mycobacterium avium-complex lung disease. Am J Respir Crit Care Med 152:1094-1096, 1995.
59. Raad I, Hachem R, Leeds N, et al: Use of adjunctive treatment with interferon-gamma in an immunocompromised patient who had refractory multidrug-resistant tuberculosis of the brain. Clin Infect Dis 22:572-574, 1996.
60. Condos R, Rom WN, Schluger NW: Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet 349:1513-1515, 1997.
61. Bermudez LE, Inderlied C, Young LS: Stimulation with cytokines enhances penetration of azithromycin into human macrophages. Antimicrob Agents Chemother 35:2625-2629, 1991.
62. Murray HW, Berman JD, Wright SD: Immunochemotherapy for intracellular Leishmania donovani infection: Gamma interferon plus pentavalent antimony. J Infect Dis 157:973-978, 1988.
63. Sundar S, Murray HW: Effect of treatment with interferon-gamma alone in visceral leishmaniasis. J Infect Dis 172:1627-1629, 1995.
64. Schindler C, Darnell JE Jr: Transcriptional responses to polypeptide ligands: The JAK-STAT pathway. Annu Rev Biochem 64:621-651, 1995.
65. Rogge L, Barberis-Maino L, Biffi M, et al: Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J Exp Med 185:825-831, 1997.
66. Giosue S, Casarini M, Alemanno L, et al: Effects of aerosolized interferon-alpha in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 158:1156-1162, 1998.
67. Palmero D, Eiguchi K, Rendo P, et al: Phase II trial of recombinant interferon-alpha2b in patients with advanced intractable multidrug-resistant pulmonary tuberculosis: Long-term follow-up. Int J Tuberc Lung Dis 3:214-218, 1999.
68. Blanchard DK, Michelini-Noiris MB, Friedman H, et al: Lysis of mycobacteria-infected monocytes by IL-2-activated killer cells: Role of LFA-1. Cell Immunol 119:402-411, 1989.
69. Blanchard DK: Cytokine activation of killer cells in mycobacterial immunity. Adv Exp Med Biol 319:105-112, 1992.
70. Bermudez LE, Young LS: Natural killer cell-dependent mycobacteriostatic and mycobactericidal activity in human macrophages. J Immunol 146:265-270, 1991.
71. Bermudez LE, Stevens P, Kolonoski P, et al: Treatment of experimental disseminated Mycobacterium avium complex infection in mice with recombinant IL-2 and tumor necrosis factor. J Immunol 143:2996-3000, 1989.
72. Castro AG, Minoprio P, Appelberg R: The relative impact of bacterial virulence and host genetic background on cytokine expression during Mycobacterium avium infection of mice. Immunology 85:556-561, 1995.
73. Kaplan G, Cohn ZA: Leprosy and cell-mediated immunity. Curr Opin Immunol 3:91-96, 1991.
74. Kaplan G, Britton WJ, Hancock GE, et al: The systemic influence of recombinant interleukin 2 on the manifestations of lepromatous leprosy. J Exp Med 173:993-1006, 1991.
75. Kaplan G, Kiessling R, Teklemariam S, et al: The reconstitution of cell-mediated immunity in the cutaneous lesions of lepromatous leprosy by recombinant interleukin 2. J Exp Med 169:893-907, 1989.
76. Kaplan G, Cohn ZA, Smith KA: Rational immunotherapy with interleukin 2. Biotechnology (NY) 10:157-162, 1992.
77. Converse P, Ottenhoff TH, Teklemariam S, et al: Intradermal recombinant interleukin 2 enhances peripheral blood T-cell responses to mitogen and antigens in patients with lepromatous leprosy. Scand J Immunol 32:83-91, 1990.
78. Johnson BJ, Ress SR, Willcox P, et al: Clinical and immune responses of tuberculosis patients treated with low-dose IL-2 and multidrug therapy. Cytokines Mol Ther 1:185-196, 1995.
79. Johnson B, Bekker LG, Ress S, et al: Recombinant interleukin 2 adjunctive therapy in multidrug-resistant tuberculosis. Novartis Found Symp 217:99-106, 1998.
80. Johnson BJ, Estrada I, Shen Z, et al: Differential gene expression in response to adjunctive recombinant human interleukin-2 immunotherapy in multidrug-resistant tuberculosis patients. Infect Immun 66:2426-2433, 1998.
81. Kovacs JA, Vogel S, Albert JM, et al: Controlled trial of interleukin 2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 335:1350-1356, 1996.
82. Fulton SA, Johnsen JM, Wolf SF, et al: Interleukin-12 production by human monocytes infected with Mycobacterium tuberculosis: Role of phagocytosis. Infect Immun 64:2523-2531, 1996.
83. Flesch IE, Hess JH, Huang S, et al: Early interleukin 12 production by macrophages in response to mycobacterial infection depends on interferon gamma and tumor necrosis factor alpha. J Exp Med 181:1615-1621, 1995.
84. Bermudez LE, Wu M, Young LS: Interleukin-12-stimulated natural killer cells can activate human macrophages to inhibit growth of Mycobacterium avium. Infect Immun 63:4099-4104, 1995.
85. Cooper AM, Callahan JE, Griffin JP, et al: Old mice are able to control low-dose aerogenic infections with Mycobactedum tuberculosis. Infect Immun 63:3259-3265, 1995.
86. Holland SM, Dorman SE: Interleukin-12 (IL-12) treatment in interferon gamma refractory pulmonary M. abscessus infection: Clinical response and immunologic reconstitution. J Invest Med 46(suppl):218A, 1998.
87. Leonard JP, Sherman ML, Fisher GL, et al: Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90:2541-2548, 1997.
88. Bermudez LE, Young LS: Recombinant granulocyte-macrophage colony-stimulating factor activates human macrophages to inhibit growth or kill Mycobacterium avium complex. J Leukoc Biol 48:67-73, 1990.
89. Blanchard DK, Michelini-Norris MB, Pearson CA, et al: Production of granulocyte-macrophage colony-stimulating factor (GM-CSF) by monocytes and large granular lymphocytes stimulated with Mycobacterium avium-M. intracellulare: Activation of bactericidal activity by GM-CSF. Infect Immun 59:2396-2402, 1991.
90. Bermudez LE, Martinelli J, Petrofsky M, et al: Recombinant granulocyte-macrophage colony-stimulating factor enhances the effects of antibiotics against Mycobacterium avium complex infection in the beige mouse model. JInfect Dis 169:575-580, 1994.
91. Bermudez LE, Kemper CA, Deresinski SC: Dysfunctional monocytes from a patient with disseminated Mycobacterium kansasii infection are activated in vitro and in vivo by GM-CSF. Biotherapy 8:135-142, 1994.
92. Kemper CA, Bermudez LE, Deresinski SC: Immunomodulatory treatment of Mycobacterium avium complex bacteremia in patients with AIDS by use of recombinant granulocyte-macrophage colony-stimulating factor. J Infect Dis 177:914-920, 1998.
93. Kindler V, Sappino AP, Grau GE, et al: The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 56:731-740, 1989.
94. Flynn JL, Goldstein MM, Chan J, et al: Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2:561-572, 1995.
95. Tramontana JM, Utaipat U, Molloy A, et al: Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1:384-397, 1995.
96. Kaplan G, Mathur NK, Job CK, et al: Effect of multiple interferon gamma injections on the disposal of Mycobacterium leprae. Proc Natl Acad Sci U S A 86:8073-8077, 1989.